UPFRONT™ -
A Clinical Trial for
Patients with Newly
Diagnosed Multiple
Myeloma

Multiple myeloma is the second most common cancer of the blood. The UPFRONT™ trial will study the addition of VELCADE® to 3 active drug therapies presently being used to treat multiple myeloma.
millennium.com

velcade.com
© 2009 Millennium Pharmaceuticals, Inc.